Anti-Thrombotic Milvexian Shows Promise in Mid-Stage Study

Milvexian, a clotting factor Xia inhibitor jointly developed by Bristol Myers Squibb and Johnson & Johnson, showed efficacy in reducing the risk of postsurgical blood clots among 1,242 patients undergoing knee arthroplasty.

The phase 2 dose-finding trial tested both once- and twice-daily dosing regimens of 25 mg, 50 mg, 100 mg (once-daily only) or 200 mg relative to enoxaparin 40 mg once per day. The primary endpoint was a composite of no asymptomatic deep-vein thrombosis, confirmed symptomatic venous thromboembolism or death from any cause.

In the twice-daily milvexian regimen, the endpoint occurred in 21 percent of the 25-mg group, 11 percent of the 50-mg group, 9 percent of the 100-mg group and 8 percent of the 200-mg group.

In the once-daily group, the endpoint occurred in 25 percent of the 25-mg group, 24 percent of the 50-mg group and 7 percent of the 200-mg group. The endpoint developed in 21 percent of the enoxaparin group.